588 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Bought by Financial Perspectives Inc

Financial Perspectives Inc purchased a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 588 shares of the company’s stock, valued at approximately $142,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Slow Capital Inc. purchased a new stake in shares of BeOne Medicines in the 2nd quarter worth about $4,377,000. Public Employees Retirement System of Ohio bought a new position in BeOne Medicines during the 2nd quarter valued at about $3,491,000. Mirae Asset Global Investments Co. Ltd. bought a new position in BeOne Medicines during the 2nd quarter valued at about $926,000. Allianz Asset Management GmbH bought a new position in BeOne Medicines during the 2nd quarter valued at about $799,000. Finally, Perigon Wealth Management LLC bought a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $581,000. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ONC. Morgan Stanley raised their target price on shares of BeOne Medicines from $313.00 to $330.00 and gave the stock an “overweight” rating in a research note on Friday, June 27th. Guggenheim raised their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Barclays began coverage on shares of BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday, October 8th. Finally, Zacks Research raised shares of BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 18th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $340.30.

BeOne Medicines Stock Down 0.5%

Shares of BeOne Medicines stock opened at $316.42 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $170.99 and a 1 year high of $355.30. The firm’s 50-day moving average is $324.46 and its two-hundred day moving average is $278.60. The stock has a market cap of $34.68 billion, a price-to-earnings ratio of -182.90 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. The company had revenue of $1.32 billion for the quarter, compared to analysts’ expectations of $1.24 billion. As a group, research analysts expect that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Chan Henry Lee sold 10,671 shares of the firm’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total value of $3,739,118.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Corazon (Corsee) D. Sanders sold 2,665 shares of the firm’s stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $337.00, for a total transaction of $898,105.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 163,484 shares of company stock worth $51,324,146. Insiders own 6.62% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.